Immunotherapy and targeted drug for eyelid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two drugs, sintilimab and disitamab vedotin, for a rare type of eyelid cancer called sebaceous gland carcinoma. The goal is to see if this combination can shrink or control the cancer before surgery, potentially making it easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with sebaceous gland carcinoma of the eyelid that is locally advanced (has spread nearby but not to distant parts of the body).
- Your doctor thinks the tumor can be removed with surgery, and you are willing to have surgery.
- You are in good overall health (able to do daily activities) and your blood tests show adequate organ function.
- You have not had prior treatment with PD-1/PD-L1 inhibitors or HER2-targeted therapies.
- You do not have active autoimmune diseases, active infections like hepatitis B or C, or a history of certain lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
Hear when a new Sebaceous Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.